Published in N Engl J Med on July 27, 1978
Emergency medical treatment of anaphylactic reactions. Project Team of the Resuscitation Council (UK) J Accid Emerg Med (1999) 4.03
Role of interleukin 10 in specific immunotherapy. J Clin Invest (1998) 2.57
Allergy to insect stings: a review. J R Soc Med (1985) 1.91
Insect stings: clinical features and management. Dtsch Arztebl Int (2012) 1.84
Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65
Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J (2016) 1.40
Update on the performance and application of basophil activation tests. Curr Allergy Asthma Rep (2013) 1.13
Allergy to bee stings: a review. J R Soc Med (1980) 1.09
Insect sting anaphylaxis. Immunol Allergy Clin North Am (2007) 1.08
Immunology in the Clinic Review Series; focus on allergies: immunotherapy for food allergy. Clin Exp Immunol (2012) 0.98
Improving the management of atopic disease. Arch Dis Child (2005) 0.93
Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol (2006) 0.87
Hyposensitisation to wasp venom in six hours. Br Med J (Clin Res Ed) (1983) 0.86
Clinical immunology review series: an approach to desensitization. Clin Exp Immunol (2010) 0.85
Desensitisation today. BMJ (1990) 0.84
The future of food allergy therapeutics. Semin Immunopathol (2012) 0.84
What physicians should know about Africanized honeybees. West J Med (1995) 0.83
Decrease of IgE-dependent platelet activation in Hymenoptera hypersensitivity after specific rush desensitization. Clin Exp Immunol (1988) 0.78
Lymphocyte-mediated regulation of platelet activation during desensitization in patients with hymenoptera venom hypersensitivity. Clin Exp Immunol (1988) 0.77
Guidelines for the use of allergen immunotherapy. Canadian Society of Allergy and Clinical Immunology. CMAJ (1995) 0.77
Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms. BMC Dermatol (2002) 0.76
The sting. Can Fam Physician (1982) 0.75
Hymenoptera Venom Immunotherapy: Tolerance and Efficacy of an Ultrarush Protocol versus a Rush and a Slow Conventional Protocol. J Allergy (Cairo) (2012) 0.75
Importance of basophil activation testing in insect venom allergy. Allergy Asthma Clin Immunol (2009) 0.75
Late local allergic response to insect sting. Can Med Assoc J (1981) 0.75
Human anaphylaxis. West J Med (1986) 0.75
Update on the status of Africanized honey bees in the western states. West J Med (1999) 0.75
Venom immunotherapy modulates interleukin-4 and interferon-gamma messenger RNA expression of peripheral T lymphocytes. Immunology (1996) 0.75
Allergy and its mechanisms. Br Med J (Clin Res Ed) (1986) 0.75
Management of insect sting hypersensitivity: an update. Allergy Asthma Immunol Res (2013) 0.75
Insect sting allergy. A study from 1980 to 2003 of patients who started treatment with venom immunotherapy between 1980 and 1998. Clin Mol Allergy (2005) 0.75
Future therapies for food allergy. Hum Vaccin Immunother (2012) 0.75
Stinging insect allergy: current perspectives on venom immunotherapy. J Asthma Allergy (2015) 0.75
European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr (2002) 8.77
Studies with DNA-cellulose chromatography. I. DNA-binding proteins from Escherichia coli. Cold Spring Harb Symp Quant Biol (1968) 5.60
Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science (1968) 4.38
Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31
The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (1972) 3.51
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol (1997) 2.91
Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol (1972) 2.70
A reappraisal of sting challenges: to whom should we offer venom immunotherapy? J Allergy Clin Immunol (1994) 2.65
Anaphylaxis. N Engl J Med (1991) 2.53
Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science (1971) 2.47
Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38
Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983) 2.37
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. N Engl J Med (1974) 2.33
Inhibition of histamine release by histamine controlled by H2 receptor. Nature (1973) 2.19
IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol (1995) 2.18
Immunological aspects of allergic asthma. Annu Rev Immunol (1994) 2.17
Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest (1973) 2.16
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 2.05
The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther (1975) 2.02
Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest (1972) 1.98
Molecular identification of an IgE-dependent histamine-releasing factor. Science (1995) 1.95
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94
The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. J Immunol (1971) 1.93
Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med (1985) 1.84
Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med (1968) 1.84
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest (1971) 1.80
Human lung mast cells: purification and characterization. J Immunol (1982) 1.78
The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol (1971) 1.78
Generation of leukotrienes by purified human lung mast cells. J Clin Invest (1982) 1.77
Antigen-induced release of slow reacting substance of anaphylaxis (SRS-A rat) in rats prepared with homologous antibody. J Exp Med (1968) 1.77
The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. J Immunol (1971) 1.73
Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.72
IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest (1978) 1.71
Basophil "releasability" in patients with asthma. Am Rev Respir Dis (1980) 1.70
The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. Prostaglandins (1972) 1.67
Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65
Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am J Physiol Gastrointest Liver Physiol (2001) 1.64
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy (2001) 1.63
Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol (1973) 1.63
IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest (1973) 1.58
Routine use of penicillin skin testing on an inpatient service. N Engl J Med (1971) 1.58
Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther (2000) 1.54
Identification of basophil granulocytes as a site of allergic histamine release. J Immunol (1972) 1.52
In vitro studies of human reaginic allergy. Adv Immunol (1968) 1.50
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48
Arachidonic acid metabolism in purified human lung mast cells. J Immunol (1984) 1.47
A control system for automatic electrical stimulation of abdominal muscles to assist respiratory function in tetraplegia. Med Eng Phys (2006) 1.47
Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy (2001) 1.46
Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol (1976) 1.45
The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A23187. J Immunol (1975) 1.45
Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest (1985) 1.45
Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol (1991) 1.45
Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol (1994) 1.44
Kinins are generated during experimental rhinovirus colds. J Infect Dis (1988) 1.44
Properties of a subpopulation of T cells bearing histamine receptors. J Clin Invest (1975) 1.43
Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis (1988) 1.43
Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med (1969) 1.42
Studies on the mechanism of hypersensitivity phenomena. XI. The effect of normal human serum on the release of histamine from human leukocytes by ragweed pollen antigen. J Immunol (1966) 1.41
Cutaneous late-phase response in food-allergic children and adolescents with atopic dermatitis. Clin Exp Allergy (1993) 1.41
Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest (1983) 1.41
Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis (1990) 1.40
Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Engl J Med (1981) 1.40
Induction of histamine secretion by polycations. Biochim Biophys Acta (1980) 1.39
Insect-sting anaphylaxis. Ann Intern Med (1993) 1.39
Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis (1991) 1.38
Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med (1984) 1.38
Insect venom allergy: diagnosis and treatment. J Allergy Clin Immunol (1984) 1.37
Heterogeneity of human mast cells. J Immunol (1983) 1.37
Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol (1991) 1.37
Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res (1998) 1.36
Insect allergy: the state of the art. J Allergy Clin Immunol (1979) 1.35
Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J Immunol (1995) 1.33
Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol (1983) 1.33
Antigen-induced IgE-mediated degranulation of human basophils. Lab Invest (1980) 1.32
Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE. J Immunol (1987) 1.32
Recombinant IL-3 induces histamine release from human basophils. J Immunol (1989) 1.31
Studies on the mechanism of lymphocyte-mediated cytolysis. 3. The role of microfilaments and microtubules. J Immunol (1973) 1.31
Inhibition of the release of slow-reacting substance of anaphylaxis in the rat with diethylcarbamazine. Proc Soc Exp Biol Med (1968) 1.30
Allergy to insect stings. I. Diagnosis of IgE-mediated hymenoptera sensitivity by venom-induced histamine release. J Allergy Clin Immunol (1974) 1.30
A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol (1968) 1.28
Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J Immunol (1986) 1.28